Elanco Animal Health Inc
ELAN22.305USD
+0.215+0.97%
Handelsschluss 12/19, 16:00（ET）Kurse um 15 Minuten verzögert
11.08BMarktkapitalisierung
308.38KGV TTM
mehr Informationen über Elanco Animal Health Inc Unternehmen
Elanco Animal Health Incorporated is an animal health company delivering products and services to prevent and treat disease in farm animals and pets. The Company's product portfolio is sold in more than 90 countries and serves animals across many species, primarily dogs and cats (collectively, pet health) and cattle, poultry, swine, and sheep (collectively, farm animal). It has a diverse portfolio of products marketed under approximately 200 brands, including products for both pets and farm animals. The Company's global pet health portfolio is focused on parasiticides, vaccines and therapeutics. Its pet health products include Advantage Family, Atopica, Credelio Family, Drontal Family, Galliprant, Interceptor Plus, Milbemax, Onsior, Seresto, Trifexis, and TruCan. Its farm animal products include AviPro, Baytril, Catosal, Denagard, Experior, Hemicell, Maxiban/Monteban, Pulmotil, Rumensin, and Surmax. Its customers include consultants, veterinarians, farm animal producers and resellers.
Elanco Animal Health Inc Informationen
BörsenkürzelELAN
Name des UnternehmensElanco Animal Health Inc
IPO-datumSep 20, 2018
CEOSimmons (Jeffrey N)
Anzahl der mitarbeiter9000
WertpapierartOrdinary Share
GeschäftsjahresendeSep 20
Addresse450 Elanco Circle
StadtINDIANAPOLIS
BörseNASDAQ OMX NASDAQ Basic NYSE
LandUnited States of America
Postleitzahl46221
Telefon18773526261
Websitehttps://www.elanco.com/
BörsenkürzelELAN
IPO-datumSep 20, 2018
CEOSimmons (Jeffrey N)
Führungskräfte von Elanco Animal Health Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Jeffrey N. (Jeff) Simmons
Mr. Jeffrey N. (Jeff) Simmons
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.36M
+36.70%
Mr. David Kinard
Mr. David Kinard
Executive Vice President - Human Resources, Corporate Communications and Administration
Executive Vice President - Human Resources, Corporate Communications and Administration
205.68K
+7.83%
Mr. Lawrence Erik Kurzius
Mr. Lawrence Erik Kurzius
Independent Chairman of the Board
Independent Chairman of the Board
160.34K
+6.87%
Mr. Michael J. Harrington
Mr. Michael J. Harrington
Independent Director
Independent Director
109.58K
+10.39%
Mr. Art A. Garcia, CPA
Mr. Art A. Garcia, CPA
Independent Director
Independent Director
91.28K
+12.74%
Dr. Deborah Turner Kochevar, Ph.D.
Dr. Deborah Turner Kochevar, Ph.D.
Independent Director
Independent Director
89.71K
+12.99%
Mr. Paul S. Herendeen
Mr. Paul S. Herendeen
Independent Director
Independent Director
84.81K
+13.84%
Mr. Timothy J. (Tim) Bettington
Mr. Timothy J. (Tim) Bettington
Executive Vice President - Corporate Strategy and Market Development
Executive Vice President - Corporate Strategy and Market Development
80.40K
-22.66%
Mr. James Meer
Mr. James Meer
Senior Vice President, Chief Accounting Officer
Senior Vice President, Chief Accounting Officer
62.55K
-1.82%
Ms. Shiv O'Neill
Ms. Shiv O'Neill
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
53.92K
+100.82%
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Jeffrey N. (Jeff) Simmons
Mr. Jeffrey N. (Jeff) Simmons
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.36M
+36.70%
Mr. David Kinard
Mr. David Kinard
Executive Vice President - Human Resources, Corporate Communications and Administration
Executive Vice President - Human Resources, Corporate Communications and Administration
205.68K
+7.83%
Mr. Lawrence Erik Kurzius
Mr. Lawrence Erik Kurzius
Independent Chairman of the Board
Independent Chairman of the Board
160.34K
+6.87%
Mr. Michael J. Harrington
Mr. Michael J. Harrington
Independent Director
Independent Director
109.58K
+10.39%
Mr. Art A. Garcia, CPA
Mr. Art A. Garcia, CPA
Independent Director
Independent Director
91.28K
+12.74%
Dr. Deborah Turner Kochevar, Ph.D.
Dr. Deborah Turner Kochevar, Ph.D.
Independent Director
Independent Director
89.71K
+12.99%
Umsatzaufteilung
Währung: USDAktualisiert: Mon, Oct 6
Währung: USDAktualisiert: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Pet Health
643.00M
51.81%
Farm Animal
583.00M
46.98%
Contract Manufacturing
15.00M
1.21%
Nach RegionUSD
Name
Umsatz
Anteil
International
648.00M
52.22%
United States
593.00M
47.78%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Pet Health
643.00M
51.81%
Farm Animal
583.00M
46.98%
Contract Manufacturing
15.00M
1.21%
Aktionärsstatistik
Aktualisiert: Sun, Nov 16
Aktualisiert: Sun, Nov 16
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Dodge & Cox
16.66%
Fidelity Management & Research Company LLC
10.21%
PRIMECAP Management Company
10.05%
The Vanguard Group, Inc.
9.75%
BlackRock Institutional Trust Company, N.A.
8.13%
Andere
45.19%
Aktionäre
Aktionäre
Anteil
Dodge & Cox
16.66%
Fidelity Management & Research Company LLC
10.21%
PRIMECAP Management Company
10.05%
The Vanguard Group, Inc.
9.75%
BlackRock Institutional Trust Company, N.A.
8.13%
Andere
45.19%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
70.39%
Investment Advisor/Hedge Fund
36.66%
Hedge Fund
5.79%
Research Firm
1.90%
Individual Investor
1.13%
Pension Fund
1.08%
Bank and Trust
0.65%
Sovereign Wealth Fund
0.18%
Family Office
0.11%
Institutionelle Beteiligung
Aktualisiert: Mon, Dec 8
Aktualisiert: Mon, Dec 8
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q4
852
577.24M
120.43%
+30.91K
2025Q3
891
577.57M
121.95%
+32.95M
2025Q2
878
543.55M
113.98%
+36.20M
2025Q1
945
503.90M
116.31%
-73.53M
2024Q4
964
498.16M
117.36%
+7.74M
2024Q3
970
490.73M
118.81%
+19.54K
2024Q2
1004
491.01M
118.24%
+1.27M
2024Q1
1021
489.85M
119.72%
-100.34M
2023Q4
1018
489.74M
120.73%
-3.72M
2023Q3
1027
490.57M
119.00%
+3.49M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Dodge & Cox
82.90M
16.69%
-25.35K
-0.03%
Jun 30, 2025
Fidelity Management & Research Company LLC
48.24M
9.71%
+9.93M
+25.93%
Jun 30, 2025
PRIMECAP Management Company
51.77M
10.42%
+1.54M
+3.07%
Jun 30, 2025
The Vanguard Group, Inc.
47.65M
9.59%
-496.16K
-1.03%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
19.58M
3.94%
-484.75K
-2.42%
Jun 30, 2025
T. Rowe Price Investment Management, Inc.
19.55M
3.94%
+3.57M
+22.35%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
22.75M
4.58%
+2.28M
+11.15%
Jun 30, 2025
UBS Financial Services, Inc.
10.31M
2.08%
+5.99M
+138.56%
Jun 30, 2025
State Street Investment Management (US)
9.13M
1.84%
-125.36K
-1.35%
Jun 30, 2025
Fidelity Institutional Asset Management
16.64M
3.35%
+1.09M
+7.01%
Jun 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Dec 6
Aktualisiert: Sat, Dec 6
Name
Anteil
iShares U.S. Pharmaceuticals ETF
4.06%
Adaptiv Select ETF
3.38%
State Street SPDR S&P Pharmaceuticals ETF
3.15%
Brandes US Small-Mid Cap Value ETF
3.14%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
2.84%
VanEck Agribusiness ETF
2.3%
First Trust Health Care Alphadex Fund
1.92%
Federated Hermes MDT Large Cap Value ETF
1.9%
First Trust NASDAQ Pharmaceuticals ETF
1.33%
Invesco S&P MidCap 400 Pure Value ETF
1.22%
Mehr Anzeigen
iShares U.S. Pharmaceuticals ETF
Anteil4.06%
Adaptiv Select ETF
Anteil3.38%
State Street SPDR S&P Pharmaceuticals ETF
Anteil3.15%
Brandes US Small-Mid Cap Value ETF
Anteil3.14%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Anteil2.84%
VanEck Agribusiness ETF
Anteil2.3%
First Trust Health Care Alphadex Fund
Anteil1.92%
Federated Hermes MDT Large Cap Value ETF
Anteil1.9%
First Trust NASDAQ Pharmaceuticals ETF
Anteil1.33%
Invesco S&P MidCap 400 Pure Value ETF
Anteil1.22%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Elanco Animal Health Inc?
Die fünf größten Anteilseigner von Elanco Animal Health Inc sind:
Dodge & Cox hält 82.90M Aktien, was 16.69% der Gesamtaktien entspricht.
Fidelity Management & Research Company LLC hält 48.24M Aktien, was 9.71% der Gesamtaktien entspricht.
PRIMECAP Management Company hält 51.77M Aktien, was 10.42% der Gesamtaktien entspricht.
The Vanguard Group, Inc. hält 47.65M Aktien, was 9.59% der Gesamtaktien entspricht.
BlackRock Institutional Trust Company, N.A. hält 19.58M Aktien, was 3.94% der Gesamtaktien entspricht.
Dodge & Cox hält 82.90M Aktien, was 16.69% der Gesamtaktien entspricht.
Fidelity Management & Research Company LLC hält 48.24M Aktien, was 9.71% der Gesamtaktien entspricht.
PRIMECAP Management Company hält 51.77M Aktien, was 10.42% der Gesamtaktien entspricht.
The Vanguard Group, Inc. hält 47.65M Aktien, was 9.59% der Gesamtaktien entspricht.
BlackRock Institutional Trust Company, N.A. hält 19.58M Aktien, was 3.94% der Gesamtaktien entspricht.
Was sind die drei wichtigsten Anteilseigner-Typen von Elanco Animal Health Inc?
Die drei wichtigsten Anteilseigner-Typen von Elanco Animal Health Inc sind:
Dodge & Cox
Fidelity Management & Research Company LLC
PRIMECAP Management Company
Dodge & Cox
Fidelity Management & Research Company LLC
PRIMECAP Management Company
Wie viele Institutionen halten Anteile an Elanco Animal Health Inc (ELAN)?
Mit Stand vom 2025Q4 halten 852 Institutionen Anteile an Elanco Animal Health Inc, mit einem Gesamtmarktwert von etwa 577.24M, was 120.43% der Gesamtanteile entspricht. Im Vergleich zum 2025Q3 ist der institutionelle Aktienbesitz um -1.52% gestiegen.
Was ist die größte Einnahmequelle von Elanco Animal Health Inc?
Am FY2025Q2 erzielte das Geschäft mit Pet Health für Elanco Animal Health Inc den höchsten Umsatz in Höhe von 643.00M, was 51.81% des Gesamtumsatzes entspricht.
